SOUTH SAN FRANCISCO, Calif., April 25, 2023 (GLOBE NEWSWIRE) — Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer, today announced that it will report first quarter 2023 financial results on Wednesday, May 3, 2023, after the close…Read More
Allogene Therapeutics to Report First Quarter 2023 Financial Results on May 3 2023
